[ Inside the business ]

SNTI stock analysis

SNTI · Senti Biosciences Holdings, Inc.

Biological products, (no diagnostic substances).

Nothing unusual in its latest filings.

The future, in 7 questions

01 What's priced in?Not available

Needs today's sales, share count and price.

02 Is the wave rising?Synthetic biology · 0.6×
'20'21'22'23'24'2536
#3 of 20 mentioning it
03 Will customers keep buying?Sales +Infinity%
No customer over 10%
Backlog $0M · 4.1× salesSales +Infinity%
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Not enough data
06 Can it fund itself?0.2 yrs of cash
05 yrs10+ yrs
Shares +389.2%/yrDebt $0
07 What could break it?2 to watch
  • Going-concern warning
  • Heavy dilution

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth steady.

Sales growth +Infinity%, +Infinity%, then +Infinity% vs. a year ago.

What could go wrong

Red flags.

It has moved 2.3× the market. In the 2022 rate shock it fell -10% while the market fell 24%. Debt is covered by cash. 1 red flag in its filings.

Speculative check

Speculative.

Speculative: going-concern warning; operating loss, cash flowing out of operations, under $1B in sales; penny stock: under $5 a share with under $6M revenue. Cash runway: 0.2 years.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Decline.

It's losing cash from operations and selling assets.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

0 of 4 years.

Returns beat its 13.0% cost of capital in 0 of the last 4 years.

Future bets

36319% on research.

$27M a year on R&D. $0M on equipment and buildings.

All figures from Senti Biosciences Holdings, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.